$498.22 Million in Sales Expected for Qiagen (NYSE:QGEN) This Quarter

Brokerages expect Qiagen (NYSE:QGENGet Rating) to report sales of $498.22 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Qiagen’s earnings, with the highest sales estimate coming in at $515.26 million and the lowest estimate coming in at $489.10 million. Qiagen reported sales of $567.31 million in the same quarter last year, which suggests a negative year over year growth rate of 12.2%. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Qiagen will report full-year sales of $2.08 billion for the current year, with estimates ranging from $2.05 billion to $2.12 billion. For the next fiscal year, analysts forecast that the business will post sales of $2.10 billion, with estimates ranging from $2.04 billion to $2.15 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow Qiagen.

Qiagen (NYSE:QGENGet Rating) last announced its earnings results on Tuesday, April 26th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. The business had revenue of $628.39 million for the quarter, compared to analyst estimates of $589.95 million. Qiagen had a return on equity of 20.71% and a net margin of 26.61%. During the same period in the prior year, the company earned $0.66 EPS.

QGEN has been the topic of several recent research reports. Zacks Investment Research upgraded Qiagen from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Friday, April 22nd. DZ Bank upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Monday, January 17th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $52.92.

Shares of NYSE QGEN opened at $44.27 on Friday. The company has a quick ratio of 1.58, a current ratio of 1.90 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $10.05 billion, a P/E ratio of 17.29, a P/E/G ratio of 2.15 and a beta of 0.23. The stock’s 50-day simple moving average is $46.94 and its two-hundred day simple moving average is $50.43. Qiagen has a twelve month low of $41.32 and a twelve month high of $58.00.

A number of hedge funds have recently bought and sold shares of QGEN. CWM LLC increased its position in Qiagen by 446.2% during the 1st quarter. CWM LLC now owns 579 shares of the company’s stock valued at $28,000 after buying an additional 473 shares in the last quarter. Masso Torrence Wealth Management Inc. bought a new position in Qiagen during the 4th quarter valued at approximately $30,000. Pacer Advisors Inc. increased its position in Qiagen by 85.0% during the 4th quarter. Pacer Advisors Inc. now owns 592 shares of the company’s stock valued at $33,000 after buying an additional 272 shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in Qiagen by 75.7% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 650 shares of the company’s stock valued at $34,000 after buying an additional 280 shares in the last quarter. Finally, UMB Bank N A MO bought a new stake in shares of Qiagen in the 4th quarter worth $41,000. 55.85% of the stock is owned by institutional investors.

Qiagen Company Profile (Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

See Also

Get a free copy of the Zacks research report on Qiagen (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.